Literature DB >> 7380554

Immunostimulant activities of a lipophilic muramyl dipeptide derivative and of desmuramyl peptidolipid analogs.

M A Parant, F M Audibert, L A Chedid, M R Level, P L Lefrancier, J P Choay, E Lederer.   

Abstract

The immunostimulant properties of a new muramyl dipeptide (MDP) derivative bearing a lipophilic moiety on the C-terminal end of the peptide chain are described. It is shown, in particular, that 1,O-(acetylmuramyl-L-alanyl-D-isoglutamine-L-alanyl)-glycerol-3-mycolate had increased immunostimulant activity in comparison with MDP. It induced hypersensitivity even when administered with an antigen in saline, and it gave higher protection against bacterial infections than did MDP. A quite unexpected finding was obtained with the corresponding desmuramyl compound 1,O-(L-alanyl-D-isoglutamine-L-alanyl)-glycerol-3-mycolate, which had no activity in producing humoral antibodies but was just as active as the muramic acid-containing compound in stimulating nonspecific resistance to bacterial infections. It was not pyrogenic. Modifications of the peptide moiety or the lipid moiety of this peptidolipid led to decrease, or even loss, of activity. These results show the importance of the N-acetylmuramyl moiety in MDP for humoral antibody production. The peptidolipid 1,O-(L-alanyl-D-isoglutamine-L-alanyl)-glycerol-3-mycolate is the first member of a new category of nonspecific immunostimulants.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7380554      PMCID: PMC550846          DOI: 10.1128/iai.27.3.826-831.1980

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  15 in total

1.  Distinctive adjuvanticity of synthetic analogs of mycobacterial water-soluble components.

Authors:  F Audibert; L Chédid; P Lefrancier; J Choay
Journal:  Cell Immunol       Date:  1976-02       Impact factor: 4.868

2.  Adjuvant activity of synthetic cell-wall peptidoglycan subunits on monoazobenzenearsonate-N-acetyl-L-tyrosine and bacterial alpha-amylase in guinea pigs.

Authors:  I Azuma; K Sugimura; Y Yamamura; S Kusumoto; Y Tarumi
Journal:  Jpn J Microbiol       Date:  1976-02

Review 3.  Biological activities of muramyl dipeptide, a synthetic glycopeptide analogous to bacterial immunoregulating agents.

Authors:  L Chedid; F Audibert; A G Johnson
Journal:  Prog Allergy       Date:  1978

4.  Minimal structural requirements for adjuvant activity of bacterial peptidoglycan derivatives.

Authors:  F Ellouz; A Adam; R Ciorbaru; E Lederer
Journal:  Biochem Biophys Res Commun       Date:  1974-08-19       Impact factor: 3.575

5.  Correlation between the immunoadjuvant activities and pyrogenicities of synthetic N-acetylmuramyl-peptides or -amino acids.

Authors:  S Kotani; Y Watanabe; T Shimono; K Harada; T Shiba
Journal:  Biken J       Date:  1976-03

6.  In vivo and in vitro stimulation of nonspecific immunity by the beta-D-p-aminophenyl glycoside of N-acetylmuramyl-L-alanyl-D-isoglutamine and an oligomer prepared by cross-linking with glutaraldehyde.

Authors:  M Parant; C Damais; F Audibert; F Parant; L Chedid; E Sache; P Lefrancier; J Choay; E Lederer
Journal:  J Infect Dis       Date:  1978-09       Impact factor: 5.226

7.  Enhancement of nonspecific immunity to Klebsiella pneumoniae infection by a synthetic immunoadjuvant (N-acetylmuramyl-L-alanyl-D-isoglutamine) and several analogs.

Authors:  L Chedid; M Parant; F Parant; P Lefrancher; J Choay; E Lederer
Journal:  Proc Natl Acad Sci U S A       Date:  1977-05       Impact factor: 11.205

8.  Enhancement of the neonate's nonspecific immunity to Klebsiella infection by muramyl dipeptide, a synthetic immunoadjuvant.

Authors:  M Parant; F Parant; L Chedid
Journal:  Proc Natl Acad Sci U S A       Date:  1978-07       Impact factor: 11.205

9.  Immunoadjuvant activities of synthetic N-acetyl-muramyl-peptides or -amino acids.

Authors:  S Kotani; Y Watanabe; F Kinoshita; T Shimono; I Morisaki
Journal:  Biken J       Date:  1975-06

10.  Immunoadjuvant activities of synthetic 6-O-acyl-N-acetylmuramyl-L-alanyl-D-isoglutamine with special reference to the effect of its administration with liposomes.

Authors:  S Kotani; F Kinoshita; I Morisaki; T Shimono; T Okunaga; H Takada; M Tsujimoto; Y Watanabe; K Kato; T Shiba; S Kusumoto; S Okada
Journal:  Biken J       Date:  1977-12
View more
  18 in total

Review 1.  Unleashing the therapeutic potential of NOD-like receptors.

Authors:  Kaoru Geddes; João G Magalhães; Stephen E Girardin
Journal:  Nat Rev Drug Discov       Date:  2009-06       Impact factor: 84.694

2.  Free versus liposome-encapsulated muramyl tripeptide phosphatidylethanolamide in treatment of experimental Klebsiella pneumoniae infection.

Authors:  P M Melissen; W van Vianen; Y Rijsbergen; I A Bakker-Woudenberg
Journal:  Infect Immun       Date:  1992-01       Impact factor: 3.441

Review 3.  Unleashing the potential of NOD- and Toll-like agonists as vaccine adjuvants.

Authors:  Charles Maisonneuve; Sylvie Bertholet; Dana J Philpott; Ennio De Gregorio
Journal:  Proc Natl Acad Sci U S A       Date:  2014-08-18       Impact factor: 11.205

Review 4.  Immunomodulating peptides.

Authors:  G H Werner; F Floc'h; D Migliore-Samour; P Jollès
Journal:  Experientia       Date:  1986-05-15

Review 5.  Muramyl peptides. Chemical structure, biological activity and mechanism of action.

Authors:  A Adam; J F Petit; P Lefrancier; E Lederer
Journal:  Mol Cell Biochem       Date:  1981-12-04       Impact factor: 3.396

6.  Effects of muramyl dipeptide treatment on resistance to infection with Toxoplasma gondii in mice.

Authors:  J L Krahenbuhl; S D Sharma; R W Ferraresi; J S Remington
Journal:  Infect Immun       Date:  1981-02       Impact factor: 3.441

7.  Effects of muramyl dipeptide on superoxide anion release and on anti-microbial activity of human macrophages.

Authors:  C B Wilson; J Bohnsack; W M Weaver
Journal:  Clin Exp Immunol       Date:  1982-08       Impact factor: 4.330

8.  Persistent enhancement of cell-mediated and antibody immune responses after administration of muramyl dipeptide derivatives with antigen in metabolizable oil.

Authors:  C Carelli; F Audibert; L Chedid
Journal:  Infect Immun       Date:  1981-07       Impact factor: 3.441

9.  Comparison of immunomodulatory activities in mice and guinea pigs of a synthetic desmuramyl peptidolipid triglymyc.

Authors:  C D Leclerc; F M Audibert; L A Chedid; E J Deriaud; N K Masihi; E Lederer
Journal:  Infect Immun       Date:  1984-03       Impact factor: 3.441

10.  Effects of natural or synthetic microbial adjuvants on induction of autoimmune thyroiditis.

Authors:  Y C Kong; F Audibert; A A Giraldo; N R Rose; L Chedid
Journal:  Infect Immun       Date:  1985-07       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.